Category Archives: Prevention

The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving TAF/FTC/DTG, TDF/FTC/DTG or TDF/FTC/EFV

2021

Objective: Integrase inhibitors, including dolutegravir (DTG), are associated with weight gain and obesity, especially when combined with tenofovir alafenamide (TAF). Obesity increases the risk of adverse pregnancy outcomes (APOs). This study...

Factors associated with methamphetamine use among men who have sex with men

2021

An abundance of literature details problematic sexualized drug use among men who have sex with men; additionally, several interventions attempt to address methamphetamine dependence in this population. Several factors are...

Effectiveness of and best practices for using contingency management and incentives for health care issues related to HIV, sexually transmitted infections (STIs), and pre-exposure prophylaxis (PrEP)

2021

Using contingency management and incentives at the different steps of HIV care continuum (such as testing, treatment adherence, viral suppressions) is widely explored and discussed in the literature, whereas the...

mHealth in the prevention of sexually transmitted infections STIs

2020

The objective of this study was to analyze in the literature how the applications were developed and how they influence the prevention of Sexually Transmitted Infections (STIs). PubMed, CAPES Periodicals...

Best practices of same-day HIV pre-exposure prophylaxis (PrEP) initiation

2021

Several clinics have implemented same-day PrEP programs and have reported that clinics offering this model of care, in general, have positive health outcomes. Studies also report that same-day PrEP is...

Is polygyny a risk factor in the transmission of HIV in sub-Saharan Africa? A systematic review

2021

Using a systematic literature review approach, this paper focused on the role of polygyny in the spread of HIV/AIDS in sub-Saharan Africa (SSA) countries. The widespread practice of polygyny is...

Reviewing PrEP’s effect on STI incidence among men who have sex with men —Balancing increased STI screening and potential behavioral sexual risk compensation

2021

Though pre-exposure prophylaxis (PrEP) can prevent HIV acquisition, it provides no protection against bacterial sexually transmitted infections (STIs). PrEP use may increase STI acquisition due to sexual risk compensation, but...

Sexual health studies in gay and lesbian people: A critical review of the literature

2021

BACKGROUND: The subject of gay and lesbian sexual health seems to be highly understudied, at least partially due to general limitations inherent in the studies of sexuality as well as...

Association between medical male circumcision and HIV risk compensation among heterosexual men: A systematic review and meta-analysis

2021

BACKGROUND: Medical male circumcision (MMC) reduces HIV infection among heterosexual men. There are concerns MMC might prompt higher-risk sexual behaviours because of lower self-perceived risk of HIV infection. We reviewed...

Breastfeeding inequities in South Africa: Can enforcement of the WHO Code help address them? — A systematic scoping review

2021

INTRODUCTION: Suboptimal breastfeeding rates in South Africa have been attributed to the relatively easy access that women and families have had to infant formula, in part as a result of...

Pre-exposure prophylaxis (PrEP) for HIV infection in cisgender and transgender women in the U.S.: A narrative review of the literature

2021

Using a socioecological approach, this review describes the peer-reviewed literature on oral pre-exposure prophylaxis (PrEP) among both cisgender (cis women) and transgender women (trans women) in the U.S. A search...

Safety and pharmacokinetic profiles of long-acting injectable antiretroviral drugs for HIV-1 pre-exposure prophylaxis: A systematic review and meta-analysis of randomized trials

2021

Objectives: To investigate the safety and pharmacokinetic profiles of long-acting injectable pre-exposure prophylaxis (LAI PrEP), notably cabotegravir (CAB-LA) and rilpivirine (RPV-LA), for the prevention of human immunodeficiency virus-1 (HIV-1) infection....

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!